Randomized trial of pimecrolimus cream plus colchicine tablets versus colchicine tablets in the treatment of genital ulcers in Behçet's disease

Dermatology

Volumn 218, Issue 2, 2009, Pages 140-145

  Köse, Osman ^a   Dinç, Ayhan ^a   Şimşek, Ismail ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Beh et's disease; Colchicine; Genital ulcers; Pimecrolimus

Indexed keywords

COLCHICINE; PIMECROLIMUS;

ADULT; ANALGESIA; ARTICLE; BEHCET DISEASE; BURN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENITAL ULCER; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION;

ADULT; BEHCET SYNDROME; COLCHICINE; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; EMOLLIENTS; FEMALE; GENITAL DISEASES, FEMALE; GENITAL DISEASES, MALE; HUMANS; MALE; PAIN; PAIN MEASUREMENT; RETROSPECTIVE STUDIES; SCROTUM; TABLETS; TACROLIMUS; TREATMENT OUTCOME; TURKEY; ULCER; VAGINA;

EID: 59049099968     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000182257     Document Type: Article

References (18)

1. Alpsoy E, Dönmez L, Önder M, Günaşti S, Usta A, Karincaoglu Y, et al: Clinical features and natural course of Behçet's disease in 661 cases: a multicentre study. Br J Dermatol 2007;157:901-906.
2. Direskeneli H: Autoimmunity vs. autoinflammation in Behçet's disease: do we over-simplify a complex disorder? Rheumatology 2006;45:1461-1465.
3. Yazici H, Fresko İ, Yurdakul S: Behcet's syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 2007;3:148-155.
4. International Study Group for Behcet's disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078-1080.
5. Önder M, Gürer MA: The multiple faces of Behçet's disease and its aetiological factors. J Eur Acad Dermatol Venereol 2001;15:126-136.
6. Lin P, Liang G: Behçet disease recommendation for clinical management of mucocutaneous lesions. J Clin Rheumatol 2006;12:282-286.
7. Alpsoy E, Er H, Durusoy C, Yilmaz E: The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease. Arch Dermatol 1999;135:529-532.
8. Bacanli A, Yerebakan Dicle O, Parmaksizoglu B, Yilmaz E, Alpsoy E: Topical granulocyte colony-stimulated factor for the treatment of oral and genital ulcers of patients with Behçet's disease. J Eur Acad Dermatol Venereol 2006;20:931-935.
9. Avci O, Gurler N, Gunes AT: Efficacy of cyclosporine on mucocutaneous manifestations of Behçet's disease. J Am Acad Dermatol 1999;36:796-797.
10. Yurdakul S, Mat C, Tüzün Y, Özyazgan Y, Hamuryudan V, Uysal Ö, et al: A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum 2001;4:2686-2692.
11. Simon D, Lübbe J, Wüthrich B, Wiesner A, Weber MM, Laffitte E, et al: Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice. Dermatology 2006;213:313-318.
12. Stuetz A, Baumann K, Grassberger M, Wolff K, Meingassner JG: Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus. Int Arch Allergy Immunol 2006;141:199-212.
13. Luger T, Paul C: Potential new indications of topical calcineurin inhibitors. Dermatology 2007;215(suppl 1):45-54.
14. Mat MC, Goksugur N, Engin B, Yurdakul S, Yazici H: The frequency of scarring after genital ulcers in Behçet's syndrome: a prospective study. Int J Dermatol 2006;45:554-556.
15. Hafner C, Hohenleutner U, Babilas P, Landthaler M, Vogt T: Targeting T cells to hit B cells: successful treatment of cutaneous plasmacytosis with topical pimecrolimus. Dermatology 2006;213:163-165.
16. Georgala S, Gregoriou S, Georgala C, Papaioannou D, Befon A, Kalogeromitros D, et al: Pimecrolimus 1% cream in nonspecific inflammatory recurrent balanitis. Dermatology 2007;215:209-212.
17. Önder M, Güler Ozden M, Gürer MA: Topical pimecrolimus 1% cream for genital ulcer treatment in Behçet's cases - preliminary report (abstract). Clin Exp Rheumatol 2004;22(suppl 34):S120.
18. Margolis DJ, Hoffsad O, Bilker W: Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007;214:289-295.